Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levosimendan in Acute Kidney Injury Study
NL-OMON43813Phase 3Withdrawn
- Sponsor
- VieCuri Medisch Centrum
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of levosimendan in acute kidney failure (AKF) (2 arms), sponsored by VieCuri Medisch Centrum. Primary endpoint: Improvement in kidney function by estimated creatinine clearance. Planned start Mar 2014; status: withdrawn.
02
Drugs
levosimendan
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on NL-OMON43813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43813.